ACM
NKTR icon

Aquatic Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Aquatic Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-57,014
Closed -$4.1M – 1576
2026
Q1 		$4.1M Buy
57,014
+1,774
+3% +$101K 0.12% 230
2025
Q4 		$2.34M Buy
+55,240
New +$3.09M 0.07% 345
2023
Q1 		– Sell
-4,633
Closed -$157K – 1595
2022
Q4 		$157K Buy
4,633
+2,626
+131% +$127K 0.01% 786
2022
Q3 		$96K Buy
+2,007
New +$119K 0.01% 759

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aquatic Capital Management's NKTR Position: Q2 2026 in Review

Aquatic Capital Management sold out of Nektar Therapeutics (NKTR) in Q2 2026, closing a stake of 57,014 shares — an estimated $4.1M sold.

Aquatic Capital Management first reported a position in NKTR in Q3 2022 and held it in 4 quarters. The position peaked at $4.1M in Q1 2026. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Aquatic Capital Management reported no remaining Nektar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Aquatic Capital Management sold 57,014 Nektar Therapeutics shares in Q2 2026, an estimated $4.1M.
  • Aquatic Capital Management first reported a position in Nektar Therapeutics in Q3 2022 and held it in 4 quarters.
  • Aquatic Capital Management's Nektar Therapeutics position peaked at $4.1M in Q1 2026.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.